Myopia Profile

MiSight® 1 day

MiSight® 1 day is safe, well-tolerated, and has the longest and most robust data available on its safety and efficacy of any soft contact lens option for myopia control. It can be considered a first-line treatment for myopia correction and control. It is also the first and currently only myopia control intervention which has received United States FDA indication for myopia control. The MiSight® 1 day dual-focus contact lens has been demonstrated in two randomized clinical trials (two years' and three years' duration) to have a high safety profile, be effective, and well accepted by myopic children. It has the longest dataset available of any myopia controlling soft contact lens, with clinical study results published for up to six years and reported for up to seven years.

Visit the MiSight® 1 day website.

Soft contact lenses
CooperVision MiSight® 1 day
Dual-focus daily disposable contact lens for myopia control
Soft contact lenses with a central correction zone surrounded by a series of treatment and correction zones producing 2.00 D of simultaneous myopic retinal defocus
-0.25D to -10.00D (spherical powers only, 0.50D steps after -6.00D)
Omafilcon A; non-ionic hydrogel (60% water), Dk/t 28
Fit on best vision spherical refraction and allow settling time
Platinum Sponsor Soft contact lenses

MiSight® 1 day Information

Product disclaimer

FDA Indications for use (US only): MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤0.75 diopters of astigmatism. The lens is to be discarded after each removal.

Availability of interventions with regulatory indications to slow progression of myopia varies by country. CooperVision does not endorse off label prescribing of interventions for myopia control. 

MiSight® 1 day articles in Myopia Profile

Five things we know about MiSight 1 dayThe MiSight 1 day clinical trial is the longest multisite study in myopia control. Here's what we've learnt a lot along the way.Read Full Article Mastering MiSight 1 dayEverything you need to know to master MiSight 1 day for myopia control - fitting, handling, vision and follow up outcomes.Read Full Article Six-year MiSight 1 day clinical trial dataThe MiSight 1 day clinical trial is the longest in soft lens myopia control, showing efficacy in children and teens in up to 6 years of wear.Read Full Article
Five things we know about MiSight 1 dayThe MiSight 1 day clinical trial is the longest multisite study in myopia control. Here's what we've learnt a lot along the way.Read Full Article

CooperVision resources

MP_CVI_interview_cover image.png

New six year MiSight® 1 day research interview

In this interview, Paul Gifford and Kate Gifford of Myopia Profile chat to Arthur Bradley and Paul Chamberlain, CooperVision R&D leaders, about their newly published paper in Ophthalmic and Physiological Optics which explores a novel analysis on the cumulative treatment effect and efficacy of MiSight 1 day, from the six year clinical study. 

Watch the interview here
One thing cover image.png

One Thing - my myopia management journey

As part of Myopia Action Month in September 2023, CooperVision asked myopia experts around the world "What's the one thing that motivated you to start with myopia management?" Listen to leaders in the field discuss their journey into myopia management, and what they have learnt along the way.

Watch the video here
Screenshot 2023-09-28 165809.jpg

The MiSight® 1 day Story

MiSight® 1 day contact lenses hold the largest body of evidence for childhood myopia management with soft contact lenses - listen to experts and researchers discuss the science behind MiSight® 1 day , and how this extensive and compelling research translates into practice.

Watch the lecture here